Quest Diagnostics (NYSE: DGX) director acquires shares through dividend reinvestment

Rhea-AI Filing Summary

Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gregg Vicky B

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	68	$194.698	$13K

Holdings After Transaction: Common Stock — 17,172 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 68 shares Acquisition price: $194.698 per share Total holdings after transaction: 17,172 shares

3 metrics

Shares acquired 68 shares Common stock acquired on April 20, 2026 via dividend reinvestment

Acquisition price $194.698 per share Price for common stock acquired on April 20, 2026

Total holdings after transaction 17,172 shares Direct ownership following April 20, 2026 acquisition

Key Terms

dividend reinvestment plan, Form 5, Form 4, Grant, award, or other acquisition

4 terms

dividend reinvestment plan financial

"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Form 5 regulatory

"eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4."

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

Form 4 regulatory

"The reporting person has chosen to report such transaction early on this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gregg Vicky B

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A	V	68(1)	A	$194.698	17,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Vicky B. Gregg	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Quest Diagnostics (DGX) report for Vicky B. Gregg?

Quest Diagnostics director Vicky B. Gregg reported acquiring 68 shares of common stock. The shares were obtained on April 20, 2026, through a broker-administered dividend reinvestment plan and were reported early on Form 4, even though they qualified for deferred Form 5 reporting.

How many Quest Diagnostics (DGX) shares does Vicky B. Gregg now hold after this Form 4?

After this transaction, Vicky B. Gregg directly holds 17,172 shares of Quest Diagnostics common stock. This total reflects the addition of 68 shares acquired on April 20, 2026, through a dividend reinvestment plan administered by her broker and reported on Form 4.

What was the price per share for the Quest Diagnostics (DGX) dividend reinvestment acquisition?

The 68 Quest Diagnostics shares were acquired at $194.698 per share. This price applies to the common stock shares obtained on April 20, 2026, through the broker-administered dividend reinvestment plan and disclosed as a grant or award-type acquisition on Form 4.

Why was this Quest Diagnostics (DGX) dividend reinvestment transaction reported on Form 4?

The dividend reinvestment transaction was eligible for deferred reporting on Form 5, but the reporting person chose to disclose it earlier on Form 4. This early reporting covers the 68 shares acquired through a broker-administered dividend reinvestment plan on April 20, 2026.

What does the transaction code 'A' mean in this Quest Diagnostics (DGX) Form 4?

In this Form 4, transaction code “A” represents a grant, award, or other acquisition of common stock. Here, it refers to 68 shares acquired on April 20, 2026, through a dividend reinvestment plan, increasing the director’s direct holdings to 17,172 shares.